Ambien
(Zolpidem Tartrate)ApprovedSmall molecule
SanofiZolpidem is used to help people fall asleep at the beginning of the night. It works by slowing down brain activity to allow for sleep and is typically prescribed for short-term use.[2] Ambien is currently approved and in use across 3 indications[4].[1]
Ambien is one of 103 small molecule programs targeting Insomnia. It is currently in Approved.
3
Indications
20
Total Trials
2
Active Trials
102
Competitors
Pipeline
Status by Indication[4][1]
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Ambien
SanofiApproved
Bayer Aspirin
BayerPreclinical
Medrol
PfizerPreclinical
Amidate
PfizerPreclinical
Brethine
SanofiPreclinical
LCZ696
NovartisPreclinical
Monoferric
PPharmacosmos A/S
Preclinical
Savaysa
Daiichi SankyoPreclinical
Zemplar
AbbViePreclinical
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Insomnia10 trials
Show 7 more trials
Combined Behavioral/Pharmacological Therapy for Insomnia
Completed·—·Phase 2·NCT00044629·162 enrolled
ART2 trials
MACE2 trials
4 more indications
Fasting Conditions1 trial
Prolonged Disorders of Consciousness1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Ambien drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Zolpidem Tartrate. EMBL-EBI & Wellcome Sanger Institute.
- [5]